Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

Registration-enabling SUMMIT Part 2 initiated and actively enrolling at 40 sites globally; RP2D selected at 100 mg once-daily optimized formulation based on: 51% week 12 mean change in Total Symptom...

Related Keywords

Berlin ,Germany ,Washington ,United States ,Christi Waarich ,Frank Siebenhaar ,Andrew Robbins ,Cogent Biosciences Inc ,Twitter ,Head University Outpatient Clinic ,Data Monitoring Committee ,Nasdaq ,Bezuclastinib Clinical Development ,Linkedin ,Globenewswire Inc ,Cogent Research Team ,Institute Of Allergology ,Total Symptom Score ,Allergy Asthma ,Immunology Annual Meeting ,University Outpatient Clinic ,Chief Executive ,Patient Reported Outcomes ,Mastocytosis Symptom Severity Daily Diary ,Mast Cell Quality Of Life ,Clinical Development ,Independent Data Monitoring Committee ,Gastrointestinal Stromal Tumors ,Private Securities Litigation Reform Act ,Quarterly Report ,